Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00. Following the sale, the president now directly owns 2,936,467 shares of the company’s stock, valued at $31,772,572.94. This represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

GYRE stock traded up $1.06 during trading on Monday, hitting $12.20. 111,450 shares of the company’s stock traded hands, compared to its average volume of 75,000. Gyre Therapeutics, Inc. has a 1 year low of $8.26 and a 1 year high of $30.39. The business has a fifty day simple moving average of $12.86 and a two-hundred day simple moving average of $12.61.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new position in shares of Gyre Therapeutics in the 2nd quarter worth approximately $218,000. Rhumbline Advisers purchased a new position in Gyre Therapeutics in the second quarter worth $123,000. WINTON GROUP Ltd purchased a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $220,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter worth $166,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after buying an additional 90,557 shares during the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.